SimulationsPlus can help you respond to COVID-19
From lead discovery to re-purposing of promising existing therapies, to predicting whole-body and target tissue drug exposure, to understanding interactions between treatment and disease in both the acute and chronic setting, to de-risking clinical trials and maximizing patient benefit, Simulations Plus has the tools and expertise to move your COVID-19 drug development program forward. Watch this video to learn what our divisional Presidents have committed to fighting the COVID-19 pandemic.
Sandra Suarez-Sharp, Ph.D.
Vice President, Regulatory Affairs
Simulations Plus, Inc.
Kevin Dykstra, Ph.D.
Vice President, Consulting Services
Cognigen, a Simulations Plus Company
Hover over the elements for more information.